All In Biotech

Drug Trial Radar · NCT06682780

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

An Open-label, Dose-escalation, and Dose-expansion Phase I/II Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Efficacy of LM-2417 for Injection Alone or in Combination With Other Antitumor Agents in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Sep 17, 2025

Primary completion

Dec 25, 2028

Study completion Dec 1, 2029

Sponsor

Lead sponsor
LaNova Medicines LimitedIndustry
Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.

Conditions

  • Advanced Solid Tumor

Interventions

  • LM-2417Drug

    Q2W/Q3W,Intravenous Drip

  • DocetaxelDrug

    Q3W,Intravenous Drip

  • Toripalimab/TirelizumabDrug

    Q3W,Intravenous Drip

  • CarboplatinDrug

    Q3W,Intravenous Drip

  • NiraparibDrug

    QD,Oral Administration

  • LenvatinibDrug

    QD,Oral Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: 60 weeks
  2. Incidence of dose-limitingtoxicity (DLT)Time frame: 60 weeks
  3. Incidence of serious adverse event (SAE)Time frame: 60 weeks
  4. TemperaturesTime frame: 60 weeks
  5. Pulse in BPM(Beat per Minute)Time frame: 60 weeks
  6. Blood Pressure in mmHgTime frame: 60 weeks
  7. Weight in KgTime frame: 60 weeks
  8. Height in centimeterTime frame: 60 weeks
  9. Laboratory tests-Blood Routine examinationTime frame: 60 weeks
  10. Laboratory tests-Urine Routine testTime frame: 60 weeks
  11. Laboratory tests-Blood biochemistryTime frame: 60 weeks
  12. Laboratory tests- Coangulation functionTime frame: 60 weeks
  13. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 60 weeks
  14. 12-lead electrocardiogram (ECG) in HRTime frame: 60 weeks
  15. 12-lead electrocardiogram (ECG) in RRTime frame: 60 weeks
  16. 12-lead electrocardiogram (ECG) in PRTime frame: 60 weeks
  17. 12-lead electrocardiogram (ECG) in QRSTime frame: 60 weeks
  18. 12-lead electrocardiogram (ECG) in QTTime frame: 60 weeks
  19. 12-lead electrocardiogram (ECG) in QTcFTime frame: 60 weeks
  20. ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 60 weeks
  21. Overall Response Rate (ORR)Time frame: 76 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • FuDan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.